The Document That Decides Whether You Get Rich or Get Played
Every startup founder signs one. Almost none of them understand what they’re agreeing to.
There’s a piece of paper that circulates quietly through Silicon Valley—passed across conference tables, emailed in PDFs, reviewed in hurried late-night sessions—that has probably transferred more wealth from one group of people to another than any contract in modern business history.
It’s called a Term Sheet.
And the peculiar thing about it? It usually says, right at the top, in plain English: “This memorandum is for discussion purposes only and is not intended to be construed as a binding agreement.”
Non-binding. Just a discussion starter. Nothing to worry about. Except that’s not quite true. And the people drafting these documents know it.
What happens in the hours and days after a founder signs that piece of paper—what happens to their equity, their control, their ability to make decisions about their own company—is almost entirely determined by language that most founders never fully parse. Terms that sound reasonable in a summary but operate very differently in practice. Provisions that only reveal their teeth years later, at precisely the moment when it’s far too late to negotiate.
I spent time going deep on a textbook chapter used to train actual venture capital attorneys—a chapter called “Portfolio Company Investments: Hi-Tech Corporation—Getting to the Term Sheet.” It’s the kind of document that doesn’t circulate outside law school classrooms and VC back offices. Dense, technical, written for practitioners.
But buried inside it are some of the most clarifying insights I’ve encountered about how startup financing actually works—and who it’s designed to benefit.
Here’s what I found.
The Mythology of the “Fair Deal”
Let’s start with a fiction that gets repeated constantly in startup culture: that the relationship between a founder and a venture capitalist is a partnership of equals, two parties aligned toward the same goal, sharing risk and reward.
This is, to put it charitably, aspirational.
The document I reviewed is blunt about the asymmetry. When second-round investors (Series B) come in at a higher price per share than Series A investors, they don’t just accept that premium—they demand structural advantages in return. The text states plainly: “Investors often will insist on more favorable terms when they are paying a relatively high price for the security.”
What does “more favorable terms” look like in practice?
The Series B investors can elect a majority of your board. Not just one seat—three out of five directors. Your investors now control your company’s governance before you’ve taken a dollar of their money.
They get a liquidation preference of $5.00 per share—their entire investment back, first, before founders see anything—plus they get to participate alongside common stockholders in whatever’s left. This is called “participating preferred,” and it means investors can win on both ends of an exit.
They have anti-dilution protection, which means if you ever raise money at a lower valuation (a “down round”), the number of shares they effectively own increases—at the expense of everyone else on the cap table, including you.
And they’ve inserted redemption rights: starting 3-5 years out, they can demand their money back at the original purchase price, on a schedule, whether the company is ready or not.
None of this is predatory in isolation. But the cumulative effect is a capital structure designed to protect investors from downside risk while preserving their upside—while founders absorb the volatility in the middle.
The document is refreshingly honest about this. It describes the original Series A terms as “venture capital plain vanilla preferred”—reasonable, founder-friendly, the baseline.
The Series B terms that follow are described as “a great deal tougher.” Most founders don’t realize there’s a difference until they’re living it.
The Brilliant Tax Trap (That Protects Investors More Than Founders)
Here’s something that almost never gets discussed at the cocktail-party version of startup education: the reason venture capitalists buy Preferred Stock instead of Common Stock isn’t just about liquidation preferences and board control.
It’s about taxes. And it’s designed to solve a problem that, at first, sounds like it’s your problem as a founder.
When a company raises a financing round, the per-share price gets set. If investors bought Common Stock at $5.00 per share, and you as a founder were simultaneously buying Common Stock at $0.40 per share (because you got in early and took the risk), the IRS would look at that $4.60 gap and call it compensation income. Taxable. Immediately. On paper gains from stock you can’t sell yet.
The solution? Investors buy a different class of stock—Preferred—which carries enough additional rights and restrictions to justify a higher price under a separate valuation. Your cheap Common Stock stays cheap in the eyes of the IRS. You don’t get hit with a massive phantom income tax bill.
On the surface, this sounds like investors are doing founders a favor. And in a narrow sense, they are.
But look at what investors receive in exchange for solving this tax problem. They get priority in liquidation. They get board control. They get anti-dilution rights. They get redemption options. They get a security that converts into Common Stock at their discretion when the company succeeds, but protects their capital when it doesn’t.
The founder gets to avoid a tax bill.
It’s a trade. And once you see it framed that way, the entire structure of venture financing starts to look less like a partnership and more like a negotiated transfer of control.
The Sleight of Hand in the “Non-Binding” Term Sheet
Back to that phrase at the top: “not intended to be construed as a binding agreement.” Yes, the Term Sheet is nominally non-binding. But it contains one provision that is explicitly binding: the exclusivity clause.
Once a founder signs a Term Sheet, they typically agree that for the next 60 to 90 days, they will not “initiate, respond to or participate in any way in any discussions regarding, or accept any proposal for, any equity financing or sale of the Company other than pursuant to this Term Sheet.”
Read that again. You cannot talk to other investors. You cannot entertain acquisition offers. You cannot explore alternatives. You are locked in—legally, in a binding way—while the investors conduct their due diligence, which may or may not result in an actual investment.
What’s the investor’s obligation during this period? To negotiate in good faith toward a deal that may or may not close.
The asymmetry is stark. Your options are foreclosed. Theirs remain open.
And then there’s the psychological dimension. The chapter notes that “many venture capital investors believe that a company is less likely to back out when a Term Sheet has been signed.” Even when the document is legally non-binding, the act of signing creates a social and reputational commitment that’s hard to walk away from.
Courts have been inconsistent in determining the enforceability of signed Term Sheets. The document is careful to note this uncertainty. But the practical effect is real: once you’ve signed, you’ve signaled. You’ve narrowed your leverage. You’ve started the clock on a process that moves at the investor’s pace.
What “Vesting” Actually Takes From You
Let’s talk about vesting, because this is where founders lose the most equity they don’t realize they’re losing.
The standard structure described in this chapter: no stock for the first year, then 25% vests, then the remaining 75% vests monthly over three years.
On paper this sounds like a standard protection mechanism—it ensures founders stay committed to the company.
In practice, it means something different: it means that at the moment of your company’s biggest inflection points—when you’re raising, when you’re getting acquired, when you’re most valuable as a negotiating entity—your equity is partially or fully unvested. And whoever controls the cap table at that moment has significant leverage over you.
Consider what happens if you’re acquired in year two. Half your stock has vested. The other half? That’s a negotiation. And you’re negotiating from a position of incomplete ownership of something you built.
The chapter also addresses the tax implications with appropriate concern. The intersection of Section 83(b) elections, Section 409A valuations, and SFAS No. 123(R) accounting rules creates a landscape where the timing and structure of your equity grants can affect your personal tax liability by orders of magnitude—without you making any different decisions about your company.
The founders at Acme Tech Corporation paid $0.10 per share for their equity. The Series A investors paid $2.00. The Series B investors paid $5.00. The difference in those prices isn’t just about valuation—it’s about tax treatment, about who bears what risk, about a legal architecture that has been refined over decades to allocate outcomes in specific ways. None of this is secret. But almost none of it is explained to founders before they sign.
The Due Diligence List They Don’t Tell You About
There’s always a Due Diligence Request List from the Investor. It’s a comprehensive catalog of everything investors want to examine before closing a deal. Corporate records. All agreements regarding securities. All financing documents. All material contracts—with suppliers, employees, customers. All litigation history and potential litigation. All intellectual property documentation. Every employee’s signed Proprietary Information and Inventions Agreement.
It runs to a dozen categories and dozens of sub-items.
Now ask yourself: when you were preparing to raise your round, did anyone give you a corresponding list of things you should understand about the investors before signing? Their fund lifecycle and how much runway they have left before they need returns? Their track record with struggling portfolio companies? Their history of enforcing redemption rights? Their relationship with other investors who might join future rounds?
Due diligence, in venture capital, runs almost entirely in one direction.
Investors spend weeks examining your company. Founders spend, at best, a few hours asking questions at partner dinners and reference calls.
The information asymmetry this creates isn’t an accident. It’s a feature of a process designed by people who have done it hundreds of times, against founders who are often doing it for the first time.
What This Means for You
I want to be clear about something: I’m not arguing that venture capital is predatory or that investors are adversaries. The point isn’t that the game is rigged. The point is that it’s a game with rules—specific, technical, consequential rules—and one side of the table understands those rules with far greater depth and precision than the other.
A few things would change this:
Read the actual documents. Not the summary. Not the “founder-friendly term sheet” blog post. The actual Certificate of Incorporation, the actual Investors’ Rights Agreement, the actual Purchase Agreement. These documents are long and technical for a reason—they have to cover every contingency. Make yourself familiar with that reason.
Understand what “participating preferred” means before you agree to it. In a small exit, participating preferred can dramatically reduce what founders take home. Model it. Run the numbers. Know what your company needs to be worth before you share meaningfully in the upside.
Know your board composition at every round. Not just after this round—at every future round. Anti-dilution provisions and board seat allocations compound. The governance structure you agree to at Series B shapes what Series C looks like.
Take the exclusivity clause seriously. It’s the most binding thing in a non-binding document. Understand what you’re agreeing to before you sign it.
Ask investors about their fund lifecycle. A fund that’s five years into a ten-year lifecycle has very different incentives than one that’s two years in. Those incentives will shape how they behave when your company hits turbulence.
None of this is designed to make you paranoid. Good investors exist. Good deals get done. Companies get built and value gets created.
But the Term Sheet is where the terms get set. And the terms you agree to when you’re excited and optimistic, in the early chapters of a company’s story, are the terms that govern everything that comes after—including the chapters where things don’t go according to plan.
If you found this useful, the best thing you can do is subscribe—this is exactly the kind of deep-dive analysis I publish for paid subscribers every week. The free tier gets the surface. Subscribers get what’s underneath it.
https://theinnovationattorney.substack.com/p/the-document-that-decides-whether?utm_source=publication-search